These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 21786278)

  • 1. Subgroup identification based on differential effect search--a recursive partitioning method for establishing response to treatment in patient subpopulations.
    Lipkovich I; Dmitrienko A; Denne J; Enas G
    Stat Med; 2011 Sep; 30(21):2601-21. PubMed ID: 21786278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subgroup identification using covariate-adjusted interaction trees.
    Steingrimsson JA; Yang J
    Stat Med; 2019 Sep; 38(21):3974-3984. PubMed ID: 31162690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tree-based recursive partitioning methods for subdividing sibpairs into relatively more homogeneous subgroups.
    Shannon WD; Province MA; Rao DC
    Genet Epidemiol; 2001 Apr; 20(3):293-306. PubMed ID: 11255239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies for identifying predictive biomarkers and subgroups with enhanced treatment effect in clinical trials using SIDES.
    Lipkovich I; Dmitrienko A
    J Biopharm Stat; 2014; 24(1):130-53. PubMed ID: 24392982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An overview of statistical planning to address subgroups in confirmatory clinical trials.
    Koch GG; Schwartz TA
    J Biopharm Stat; 2014; 24(1):72-93. PubMed ID: 24392979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population enrichment designs: case study of a large multinational trial.
    Mehta CR; Gao P
    J Biopharm Stat; 2011 Jul; 21(4):831-45. PubMed ID: 21516572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A flexible strategy for testing subgroups and overall population.
    Alosh M; Huque MF
    Stat Med; 2009 Jan; 28(1):3-23. PubMed ID: 18985704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit.
    Lachin JM
    Clin Trials; 2009 Dec; 6(6):565-73. PubMed ID: 19933716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A practical comparison of group-sequential and adaptive designs.
    Kelly PJ; Sooriyarachchi MR; Stallard N; Todd S
    J Biopharm Stat; 2005; 15(4):719-38. PubMed ID: 16022175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Test homogeneity of risk difference across subgroups in clinical trials.
    Zhang L; Yang H; Cho I
    J Biopharm Stat; 2009; 19(1):67-76. PubMed ID: 19127467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two new covariate adjustment methods for non-inferiority assessment of binary clinical trials data.
    Hou Y; Ding V; Li K; Zhou XH
    J Biopharm Stat; 2011 Jan; 21(1):77-93. PubMed ID: 21191856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Bayesian approach to subgroup identification.
    Berger JO; Wang X; Shen L
    J Biopharm Stat; 2014; 24(1):110-29. PubMed ID: 24392981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Properties of multiple intersection-union tests for multiple endpoints in combination therapy trials.
    Westfall PH; Ho SY; Prillaman BA
    J Biopharm Stat; 2001; 11(3):125-38. PubMed ID: 11725927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale for a non-inferiority clinical trial design focused on subpopulations.
    Kulkarni PM; Meadows ES; Ahuja S; Muram D; Plouffe L
    Curr Med Res Opin; 2004 Oct; 20(10):1641-7. PubMed ID: 15462697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparisons of methods for analysis of repeated binary responses with missing data.
    Frank Liu G; Zhan X
    J Biopharm Stat; 2011 May; 21(3):371-92. PubMed ID: 21442514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF trial.
    Wedel H; Demets D; Deedwania P; Fagerberg B; Goldstein S; Gottlieb S; Hjalmarson A; Kjekshus J; Waagstein F; Wikstrand J;
    Am Heart J; 2001 Sep; 142(3):502-11. PubMed ID: 11526365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adaptive covariate adjustment in clinical trials.
    Wang SJ; Hung HM
    J Biopharm Stat; 2005; 15(4):605-11. PubMed ID: 16022166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A hybrid Bayesian adaptive design for dose response trials.
    Chang M; Chow SC
    J Biopharm Stat; 2005; 15(4):677-91. PubMed ID: 16022172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implementing type I & type II error spending for two-sided group sequential designs.
    Rudser KD; Emerson SS
    Contemp Clin Trials; 2008 May; 29(3):351-8. PubMed ID: 17933592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction effects and subgroup analyses in clinical trials: more than meets the eye?
    Sevdalis N; Jacklin R
    J Eval Clin Pract; 2008 Oct; 14(5):919-22. PubMed ID: 18373582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.